Unum Therapeutics Inc (NASDAQ:UMRX) Q1 2019 Earnings Conference Call - Final Transcript
May 13, 2019 • 08:00 am ET
Thank you. (Operator Instructions) And our first question comes from Peter Lawson with SunTrust. Your line is open.
Hi, Chuck. Thanks for taking the questions. Thanks for the clinical safety updates. Just around -- when should we think about timing around updates around clinical benefits? And if there's anything you can mention about that, it would be great. And should we kind of view today's update kind of to mean that you haven't seen any clinical responses yet or you have and you're kind of holding that back for a conference?
Hi, Peter. It is Chuck. Good to talk to you this morning. Just to clarify. So I think, our intention in these calls is to provide really sort of operational updates and to give a very high level view in terms of the safety observations in each study. As we've indicated previously, our practice in terms of sharing data from the studies is really through (inaudible) medical conferences, and we provide the guidance, I think, for each of those programs in terms of approximately when we intend to be presenting those results. So there is nothing to read in terms of observations with respect to efficacy. We're essentially looking to present those again at scientific conferences.
Got you. And then the safety updates say for 17-01, how many are at that kind of higher dose level?
Yeah. Again, we haven't -- we don't like to get into the specifics in terms of individual patients. Again, the high level summary really reflects the safety observations we've seen across the entire program.
Got you. Thank you. Thanks for taking the questions.
Thank you. (Operator Instructions) Our next question comes from Yaron Werber with Cowen. Your line is open.
Good morning. Thanks for taking my questions. I just have one question regarding the ATTCK-34-01 program. I'm just wondering, if you guys can share some details on the enrollment status, like, how many cohorts or patients you'll be sharing at the end of this year?
Sure. So again, just to clarify, we don't provide sort of specifics in terms of individual patients on specific trials. We're currently enrolling and treating patients in the first dose cohort. And ultimately, depending upon the pace of enrollment, we'll be continuing to progress through additional cohorts and again, reporting data late in 2019 from the study.
I see. Okay. Thanks. That's helpful.
Thank you. And I'm currently showing no further questions at this time. I'd like to turn the call back over to Chuck Wilson for closing remarks.
Great. Thank you very much for joining us today. We look forward to continue to provide you with updates on all of our programs through the rest of this year.
Ladies and gentlemen, this concludes today's conference. Thanks for your participation. Have a wonderful day.